Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and ACP-319 in B-cell malignancies
NCT02328014Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Dec 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AMG-319 in non-Hodgkin lymphoma (NHL), multiple myeloma (MM), B cell acute lymphoblastic leukemia (B-ALL), sponsored by Acerta Pharma. Started Dec 2014; status: completed.
02
Drugs
AMG-319
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02328014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328014.